Technology & Pipeline
We are currently developing our antibiotic product candidate, OG716 as well as other homolog antibiotic product candidates, researching LBPs, and have other product candidates, including SMaRT Replacement Therapy positioned for outlicensing or partnering.
| Technology | Candidate | Indication | Development Stage | ||||
|---|---|---|---|---|---|---|---|
| Preclinical | Phase 1 | Phase 2 | Phase 3 | Market | |||
| Lantibiotics | OG716 | C.difficile |
Preclinical Phase in progress
|
Phase 1 Phase not started
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
| Live Biotherapeutics | AG013 | Oral mucositis |
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2 Phase not started
|
Phase 3 Phase not started
|
Market Phase not started
|
Lantibiotics
Lantibiotics are a class of antibiotics with a novel mechanism of action active against several multi-drug resistant organisms.
LBP
Our strategy is to develop genetically engineered safe bacterial strains designed to produce, deliver and release therapeutics locally at oral disease sites to prevent or cure a disease.